TIGIT Antibody (2629A) [Unconjugated]

HEK293 human embryonic kidney cell line transfected with either (A) cynomolgus monkey TIGIT or (B) irrelevant protein, and eGFP, was stained with Rabbit anti-cynomolgus monkey TIGIT monoclonal antibody (Catalog # MAB10532) followed by Allophycocyanin-conjugated anti-Rabbit IgG Secondary Antibody (F0111). Quadrant markers were set based on control antibody staining (MAB1050, data not shown). Staining was performed using our Staining Membrane-Associated Proteins protocol.

In a functional ELISA, Recombinant Cynomolgus Monkey TIGIT (9380-TG) binds to immobilized Recombinant Human CD155/PVR (2530-CD) coated at 2.5 µg/mL (100 µL/well) in a dose-dependent manner (orange line). Binding is blocked (green line) by increasing concentrations of Rabbit Anti-Cynomolgus Monkey TIGIT Monoclonal Antibody (Catalog # MAB10532). At 70-350 ng/mL, this antibody will block 50% of the binding.

• Reactivity: Pm-Cm
• Applications: Flow, B/N, CyTOF-ready
• Clone: 2629A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

TIGIT Antibody (2629A) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Human embryonic kidney cell HEK293-derived Cynomolgus monkey TIGIT
  Met22-Pro142
  Accession # XP_00554815
• Specificity: Detects Cynomolgus Monkey TIGIT in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction 70-350 ng/mL
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TIGIT Antibody (2629A) [Unconjugated]

• T cell immunoreceptor with Ig and ITIM domains
• TIGIT
• VSIG9
• VSTM3
• WUCAM

Background

TIGIT (T cell Immunoreceptor with Ig and ITIM domains), also called VSTM3 (V-set and transmembrane domain-containing 3), VSIG9 (V-set and Ig domain-containing 9) and WUCAM (Washington University cell adhesion molecule) is a 30-34 kDa type I transmembrane protein that is a member of the CD28 family within the Ig superfamily of proteins (1-4). Human TIGIT cDNA encodes 244 amino acids (aa) including a 21 aa signal sequence, a 120 aa extracellular region with a V-type Ig-like domain and two potential N-glycosylation site, a 21 aa transmembrane sequence, and an 82 aa cytoplasmic domain with an ITIM motif (5). A 170 aa variant diverges after aa 166 (5). Within the ECD, human TIGIT shares only 68-75% aa sequence identity with mouse, porcine, canine, equine and bovine TIGIT. Cyno TIGIT shares 88.4% homology with human TIGIT. TIGIT is expressed on NK cells and subsets of activated, memory and regulatory T cells, and particularly on follicular helper T cells within secondary lymphoid organs (1, 2, 6-8). It binds to CD155/PVR/Necl-5 and Nectin-2/CD112/PVRL2 that appear on dendritic cells (DC) and endothelium (1-3, 7). Binding of TIGIT by DC induces IL-10 release and inhibits IL-12 production (2). Ligation of TIGIT on T cells down‑regulates TCR-mediated activation and subsequent proliferation, while NK cell TIGIT ligation blocks NK cell cytotoxicity (6-8). Through CD155 and Nectin-2, which also interact with DNAM-1/CD226 and CD96/Tactile, TIGIT is part of an interacting network of Ig superfamily members that may augment or oppose each other (3, 4, 6, 7). In particular, TIGIT binding to CD155 can antagonize the effects of DNAM-1 (6, 7). Soluble TIGIT is able to compete with DNAM-1 for CD155 binding and attenuates T cell responses, while mice lacking TIGIT show increased T cell responses and susceptibility to autoimmune challenges (2, 3, 8).

1. Boles, K.S. et al. (2009) Eur. J. Immunol. 39:695.
2. Yu, X. et al. (2009) Nat. Immunol. 10:48.
3. Levin, S.D. et al. (2011) Eur. J. Immunol. 41:902.
4. Xu, Z. et al. (2010) Cell. Mol. Immunol. 7:11.
5. SwissProt Accession # Q495A1.
6. Seth, S. et al. (2009) Eur. J. Immunol. 39:3160.
7. Stanietsky, N. et al. (2009) Proc. Natl. Acad. Sci. USA 106:17858.
8. Joller, N. et al. (2011) J. Immunol. 83:1338.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • XP_00554815()